Welcome to our dedicated page for LABCORP HOLDINGS SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Labcorp Holdings Inc. filings document a public laboratory-services company with common stock listed on the New York Stock Exchange under LH. Its 8-K reports cover operating results, financial guidance, dividend declarations, board appointments, and material definitive agreements tied to financing arrangements.
Labcorp's regulatory record also includes proxy materials describing board composition, committee service, executive compensation, equity awards, shareholder voting matters and governance practices. Debt and liquidity-related filings disclose senior unsecured term-loan terms, receivables purchase arrangements, covenants and related obligations, while earnings exhibits detail results across the company's diagnostics and biopharma laboratory services activities.
Labcorp Holdings (LH) – insider sale by finance executive
Form 4 filed 07/31/2025 details that SVP & Chief Accounting Officer Peter J. Wilkinson sold a total of 202 common shares on 07/29/2025 in two open-market transactions: 102 shares at $261.0102 and 100 shares at $261.035. Estimated gross proceeds equal roughly $52.7 k. Following the sales, Wilkinson’s direct ownership fell to 1,852.2194 shares. No derivative securities were reported.
The activity modestly reduces the executive’s stake and is immaterial relative to Labcorp’s share count, though investors may note it when tracking insider sentiment.